Patrick A. Flume

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>

Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

Cystic Fibrosis Pulmonary Guidelines

Patrick A. Flume, Brian O’Sullivan, Karen A. Robinson et al. · American Journal of Respiratory and Critical Care Medicine · 2007 · 1K citations

Medicine, Clinical Sciences, Internal Medicine +9

Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research

Adam T. Hill, Charles Haworth, Stefano Aliberti et al. · European Respiratory Journal · 2017 · 448 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +11

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized Study

David E. Griffith, Gina Eagle, Rachel Thomson et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 343 citations

Medicine, Infectious Diseases, Pharmacology +17